UNNECESSARY TESTS AND TREATMENTS IN LOW VALUE CRITICAL CARE
Dr Gerben Keijzers
Senior Staff Specialist Emergency Physician,
Gold Coast Hospital at Department of Health, Queensland &
Adjunct Professor, Honorary Professor of Emergency Medicine
Griffith University & Bond University,
Queensland, Australia
RESEARCHER PROFILE
Filmed in Southport, Queensland | January 2025
Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. Dr Keijzers balances half of his time between clinical work and academic duties, including teaching medical students and conducting research. His role also include being an honorary professor of emergency medicine at Bond University and is an associate professor at Griffith University.
Dr Keijzers completed a master’s degree in epidemiology and medical degree in Nijmegen, The Netherlands. He came to Australia in 2002 and completed his Fellowship in Emergency Medicine in 2008. He has a PhD in the quality of trauma care.
He works clinically, conducts clinical research and is a clinical supervisor for medical students on emergency medicine rotation. Over the past 15 years, Dr Keijzers has helped create seven research pillars focused on critical care studies, such as sepsis and antimicrobial stewardship.
His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources.
He is the former chair of the Queensland Emergency Research Collaborative, a member of the Clinical Trials Group of the Australasian College for Emergency Medicine, a member of the Research Advisory Committee for the Emergency Care Institute and is section editor for the peer-reviewed journal Emergency Medicine Australasia.
Note: Narrative adapted from University of Queensland website and interview
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Lía Aguilar Madariaga
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
